Send to

Choose Destination
Dis Markers. 2017;2017:3098542. doi: 10.1155/2017/3098542. Epub 2017 Feb 15.

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.

Author information

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.
Department of Gynecologic Oncology, Institute for Cancer Genetics and Informatics and University of Oslo, Oslo, Norway.
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK.
DOCs International, Buckinghamshire, UK.
Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain; Department of Medical Sciences, Medical School, University of Girona, Girona, Spain.
Medical Oncology, Royal Prince Alfred Hospital and Concord Repatriation General Hospital and Chris O'Brien Lifehouse, Sydney, NSW, Australia.
Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.


Ovarian cancer patients are recognized with poor prognosis. This study aimed to identify microRNAs in plasma for predicting response to treatment and outcome. We have investigated microRNAs in plasma from ovarian cancer patients enrolled in a large multicenter study (ICON7), investigating the effect of adding bevacizumab to standard chemotherapy in patients diagnosed with epithelial ovarian cancer. Patients with different histology, grade, and FIGO stages were included (n = 207) in this study. Screening of 754 unique microRNAs was performed in the discovery phase (n = 91) using TaqMan Low Density Arrays. The results were validated using single assays and RT-qPCR. Low levels of miR-200b, miR-1274A (tRNALys5), and miR-141 were significantly associated with better survival, confirmed with log-rank test in the validation set. The level of miR-1274A (tRNALys5) correlated with outcome was especially pronounced in the high-grade serous tumors. Interestingly, low level of miR-200c was associated with 5-month prolongation of PFS when treated with bevacizumab compared to standard chemotherapy. We found prognostic significance of miR-200b, miR-141, and miR-1274A (tRNALys5) in all histological types, where miR-1274A (tRNALys5) may be a specific marker in high-grade serous tumors. The level of miR-200c may be predictive of effect of treatment with bevacizumab. However, this needs further validation.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center